Clinical Database and Biobank of Patients With Inflammatory Myopathies: the MASC Project (Myositis, DNA, Serum, Cells) (MASC)

Inflammatory Myositis Clinical Trial

— MASC  

Official title:

Clinical Database and Biobank of Patients With Inflammatory Myopathies: the MASC Project (Myositis, DNA, Serum, Cells) (MASC)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04637672
• Other study ID #: CIC-1421-20-04
• Status: Completed
• Start date: December 19, 2013
• Est. completion date: December 14, 2023

Study information

• Verified date: September 2023
• Source: Groupe Hospitalier Pitie-Salpetriere
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Myositis are rare diseases for which the development of a cohort associated with a bank of biological samples (biobank) will allow for the conduct of researches to better delineate the underlying pathophysiology and find cures. This prospective cohort of patients with myositis will allow for identification of factors favouring the occurrence of myositis, whether they are constitutional (genetic) or acquired (environmental or drug). Different subgroups of myositis used for prognostication will be identified based on clinico-demographical variables, the nature of the organs involved beyond peripheral muscles (cardiac, diaphragm) and biomarkers abnormalities.

Description:

Myositis is a rare autoimmune disease in which the immune system mistakenly attacks the patient's own peripheral muscles. This aggression manifests by muscle inflammation and necrosis responsible for a motor deficit of varying severity.

The treatments available today are insufficient and are non-specific. Biological criteria, issued from simple blood or muscle tests are missing, and they will help to define the activity of the disease and the efficacy of treatments.

The MASC protocol will include patients with myositis, and investigators will collect clinical, radiological, electrophysiological, histological and biological data to be used for researches aiming at better understanding this entity. A biobank (muscle biopsy, DNA, serum, plasma, PBMCs) will be acquired on this prospective cohort.

The study itself will be composed of a baseline visit and monthly to yearly follow-up visits which will assess:

• Clinical examination with an evaluation of the muscle strength and function impairment/handicap, including but not limited to:

• Manual testing of proximal axial and distal muscles on the five points Medical Research Council (MRC) scale

• Barré tests and Mingazzini tests, number of stand-up / sitting, leg crossing

• Biometry, lab and radiological measurements: muscle enzymes (creatine phosphokinase CPK, troponin, C-reactive protein, quantification of autoantibodies, muscle MRI, muscle biopsy, thorax tomodensitometry, pulmonary test function

• Extra-muscular evaluation: cardiac examination and work-up (echocardiography, cardiac MRI and Positron Emission Tomography (PET) scanner, cardiac biopsies), pulmonary evaluation, rheumatological and dermatological assessment, history of thromboembolic disease and cancer

Patient activity assessment: evaluation of daily life activity by both patient and physician using a Visual Analogue Scale

• Quality of life questionnaires

• Evaluation of the efficacy and toxicity of specific treatments

For each patient, the date of last visit or contact will be collected as well as outcomes, particularly for the cause of death if relevant.

Data from the biobank MASC " Muscles DNA/RNA Serum and Cells " will be added to other data. The biobank has been fully registered with local authorities and ethical committees ("Committee for Personal Protection (CPP)" CPP agreement). It contains peripheral blood mononuclear cells (PBMC), serum, DNA and RNA from blood and muscular biopsies collected at the diagnosis stage. The database contains immunological and genetical data.

This prospective study will also aim at:

• Identify the differential pathophysiological processes between the different subgroups of myositis

• Identify prognostic factors, including the different treatment modalities used

• Improve physiopathological knowledge (clinico-anatomobiological characteristics and identification of other biomarkers through the biobank)

• Improve the evaluation of the clinical outcomes/endpoints for future trials

• Develop clinical trials for homogeneous subgroups of patients, based on their pathophysiology and evaluated on the appropriate endpoints.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1273
• Est. completion date: December 14, 2023
• Est. primary completion date: December 14, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All patients who had a confirmed (muscular biopsy, electromyogram, magnetic resonance imaging) or suspected clinically myositis. Myositis criteria are as follow:

• Dermatomyositis or polymyositis according to Bohan and Peter criteria (1975)

• Body inclusion myositis according to Griggs et al. criteria (1995)

• Necrotizing autoimmune myopathy according to Hoogendijk et al. criteria (2004)

• Drug-induced myositis

• Signature of the informed consent form for the study and for the biobank

• Age over 18 years old

Exclusion Criteria:

• None

Related Conditions & MeSH terms

• Drug-induced Inflammatory Myositis
• Idiopathic Inflammatory Myositis
• Inflammatory Myositis
• Myositis

Locations

Country	Name	City	State
France	AP-HP, Pitié-Salpêtrière Hospital, Department of Internal Medicine and clinical immunology	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Groupe Hospitalier Pitie-Salpetriere

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Characterisation of the different myositis subgroups based on clinical, radiological, electrophysiological and histo-biological evaluations	Characterisation of the different myositis subgroups based on clinical, radiological, electrophysiological and histo-biological evaluations, including but not limited to: sexe, age, profession, a history of infection, cancer or other autoimmune and inflammatory diseases, diagnosis criteria, creatine phosphokinase, autoantibodies, immune systeme evaluation based on peripheral blood mononuclear cells, DNA sequencing muscular biopsies	baseline: first 30 days after inclusion
Secondary	Characterisation of the natural history of myositis subgroups :responses to treatments, prognosis factors, evolution	Characterisation of the natural history of myositis subgroups :responses to treatments, prognosis factors, evolution	up to twenty years after inclusion
Secondary	Characterisation of an immune system signature, using peripheral blood mononuclear cells and muscular biopsies, DNA and RNA sequencing, and autoantibodies	Characterisation of an immune system signature, using peripheral blood mononuclear cells and muscular biopsies, DNA and RNA sequencing, and autoantibodies	baseline: first 30 days after inclusion
Secondary	Risk factors for All-cause mortality depending on patient's and disease characteristics	Risk factors for All-cause mortality depending on patient's and disease characteristics including clinical, radiological electrophysiological, histo-biological and immunological as well as treatment received stratified by each subgroup of myositis	up to twenty years after inclusion
Secondary	Change of the quality of life, using quality of life questionnaires, depending of patients and disease characteristics	Change of the quality of life, using quality of life questionnaires, depending of patients and disease characteristics	up to twenty years after inclusion
Secondary	Change of activity impairment using an evaluation of daily life activity by both patient and physician using a Visual Analogue Scale depending of patients and disease characteristics	Change of activity impairment using an evaluation of daily life activity by both patient and physician using a Visual Analogue Scale depending of patients and disease characteristics	up to twenty years after inclusion
Secondary	Characterisation of a quality-of-life scale using biological data (CPK), muscle weakness (muscle testing) and other visceral involvements	Characterisation of a quality-of-life scale using biological data (CPK), muscle weakness (muscle testing) and other visceral involvements	up to twenty years after inclusion
Secondary	Characterisation of a global activity scale using biological data (CPK), muscle weakness (muscle testing) and other visceral involvements	Characterisation of a global activity scale using biological data (CPK), muscle weakness (muscle testing) and other visceral involvements	up to twenty years after inclusion
Secondary	Incidence of major cardio-vascular events	Incidence of major cardio-vascular events	up to twenty years after inclusion
Secondary	Consequences on outcomes of major cardio-vascular events	Consequences on outcomes of major cardio-vascular events	up to twenty years after inclusion
Secondary	Correlation of myositis with the development of extra-muscular diseases including but not limited to dermatological, rheumatological, cardiological and pneumological associated diseases	Correlation of myositis with the development of extra-muscular diseases including but not limited to dermatological, rheumatological, cardiological and pneumological associated diseases	up to twenty years after inclusion
Secondary	Characterisation of respiratory function with pulmonary function test and thoracic tomodensitometry	Characterisation of respiratory function with pulmonary function test and thoracic tomodensitometry	up to twenty years after inclusion
Secondary	Characterisation of diaphragmatic failure with pulmonary function test and thoracic tomodensitometry	Characterisation of diaphragmatic failure with pulmonary function test and thoracic tomodensitometry	up to twenty years after inclusion
Secondary	Follow up of respiratory function with pulmonary function test and thoracic tomodensitometry	Follow up of respiratory function with pulmonary function test and thoracic tomodensitometry	up to twenty years after inclusion
Secondary	Follow up of diaphragmatic failure with pulmonary function test and thoracic tomodensitometry	Follow up of diaphragmatic failure with pulmonary function test and thoracic tomodensitometry	up to twenty years after inclusion